Immunotoxin-based targeted therapy for cancer
AssigneeThe Regents of the University of Colorado, a body corporate
InventorsZhirui Wang, Zhaohui Wang, Bradley Haverkos
Life of this patent
Estimating the term…
Abstract
Methods of treating various types of cancer, including cutaneous T-cell lymphoma, involve administering a therapeutically effective amount of a pharmaceutical composition containing a genetically engineered C-C motif chemokine receptor 4 bispecific immunotoxin, alone, or in combination with one or more additional therapeutic agents, such as a pharmaceutical composition containing an antibody-drug conjugate.
Claims20
A method of treating or alleviating at least one symptom of cutaneous T-cell lymphoma in a subject, comprising:
- administering to the subject a therapeutically effective amount of a genetically engineered C-C motif chemokine receptor 4 bispecific immunotoxin (“CCR4-IL2 bispecific immunotoxin”) and a therapeutically effective amount of an anti-CD30 antibody-drug conjugate.
A system for treating or alleviating at least one symptom of cutaneous T-cell lymphoma in a subject diagnosed with cutaneous T-cell lymphoma, the system comprising:
- at least one injection device configured to administer to the subject a therapeutically effective amount of a first pharmaceutical composition comprising a genetically engineered CCR4-IL2 bispecific immunotoxin and a therapeutically effective amount of a second pharmaceutical composition comprising an anti-CD30 antibody-drug conjugate.
Dependencies are inferred from the claim text.